147 related articles for article (PubMed ID: 29757380)
1. Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.
Kip AE; Castro MDM; Gomez MA; Cossio A; Schellens JHM; Beijnen JH; Saravia NG; Dorlo TPC
J Antimicrob Chemother; 2018 Aug; 73(8):2104-2111. PubMed ID: 29757380
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Dorlo TP; van Thiel PP; Huitema AD; Keizer RJ; de Vries HJ; Beijnen JH; de Vries PJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2855-60. PubMed ID: 18519729
[TBL] [Abstract][Full Text] [Related]
5. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Dorlo TP; Huitema AD; Beijnen JH; de Vries PJ
Antimicrob Agents Chemother; 2012 Jul; 56(7):3864-72. PubMed ID: 22585212
[TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Dorlo TPC; Kip AE; Younis BM; Ellis SJ; Alves F; Beijnen JH; Njenga S; Kirigi G; Hailu A; Olobo J; Musa AM; Balasegaram M; Wasunna M; Karlsson MO; Khalil EAG
J Antimicrob Chemother; 2017 Nov; 72(11):3131-3140. PubMed ID: 28961737
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
8. Assessing Dose-Exposure-Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach.
Madu SJ; Wang K; Chirumamilla SK; Turner DB; Steel PG; Li M
Pharm Res; 2023 Dec; 40(12):2983-3000. PubMed ID: 37816929
[TBL] [Abstract][Full Text] [Related]
9. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
[TBL] [Abstract][Full Text] [Related]
10. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.
Palić S; Beijnen JH; Dorlo TPC
Int J Antimicrob Agents; 2022 Jan; 59(1):106459. PubMed ID: 34695563
[TBL] [Abstract][Full Text] [Related]
11. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.
Kip AE; Rosing H; Hillebrand MJ; Castro MM; Gomez MA; Schellens JH; Beijnen JH; Dorlo TP
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Aug; 998-999():57-62. PubMed ID: 26160472
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
Palić S; Kip AE; Beijnen JH; Mbui J; Musa A; Solomos A; Wasunna M; Olobo J; Alves F; Dorlo TPC
J Antimicrob Chemother; 2020 Nov; 75(11):3260-3268. PubMed ID: 32780098
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
[TBL] [Abstract][Full Text] [Related]
15. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
16. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
[TBL] [Abstract][Full Text] [Related]
17. Miltefosine to treat leishmaniasis.
Berman J
Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
[TBL] [Abstract][Full Text] [Related]
18. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
[TBL] [Abstract][Full Text] [Related]
20. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.
Obonaga R; Fernández OL; Valderrama L; Rubiano LC; Castro Mdel M; Barrera MC; Gomez MA; Gore Saravia N
Antimicrob Agents Chemother; 2014; 58(1):144-52. PubMed ID: 24145529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
